Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With Campylobacter jejuni Infection

OBJECTIVE: To identify the clinical phenotypes and infectious triggers in the 2019 Peruvian Guillain-Barré syndrome (GBS) outbreak. METHODS: We prospectively collected clinical and neurophysiologic data of patients with GBS admitted to a tertiary hospital in Lima, Peru, between May and August 2019. Molecular, immunologic, and microbiological methods were used to identify causative infectious agents. Sera from 41 controls were compared with cases for antibodies to Campylobacter jejuni and gangliosides. Genomic analysis was performed on 4 C jejuni isolates. RESULTS: The 49 included patients had a median age of 44 years (interquartile range [IQR] 30-54 years), and 28 (57%) were male. Thirty-two (65%) had symptoms of a preceding infection: 24 (49%) diarrhea and 13 (27%) upper respiratory tract infection. The median time between infectious to neurologic symptoms was 3 days (IQR 2-9 days). Eighty percent had a pure motor form of GBS, 21 (43%) had the axonal electrophysiologic subtype, and 18% the demyelinating subtype. Evidence of recent C jejuni infection was found in 28/43 (65%). No evidence of recent arbovirus infection was found. Twenty-three cases vs 11 controls (OR 3.3, confidence interval [CI] 95% 1.2-9.2, p < 0.01) had IgM and/or IgA antibodies against C jejuni. Anti-GM1:phosphatidylserine and/or anti-GT1a:GM1 heteromeric complex antibodies were strongly positive in cases (92.9% sensitivity and 68.3% specificity). Genomic analysis showed that the C jejuni strains were closely related and had the Asn51 polymorphism at cstII gene. CONCLUSIONS: Our study indicates that the 2019 Peruvian GBS outbreak was associated with C jejuni infection and that the C jejuni strains linked to GBS circulate widely in different parts of the world

New World Monkey Aotus nancymae as a Model for Campylobacter jejuni Infection and Immunity

Three groups of six monkeys (Aotus nancymae) each were inoculated intragastrically with increasing doses of Campylobacter jejuni. Infection resulted in fecal colonization (100% of monkeys), dose-related diarrhea, and robust immune responses. Colonization duration and diarrhea rate were reduced upon secondary challenge. A. nancymae may be useful for studying anti-Campylobacter vaccine efficacy

Severity of the gastroenteritis caused by Vibrio parahaemolyticus of the pand emic group in Peru

Objective. To determine the epidemiological and clinic characteristics of gastroenteritis caused by Vibrio parahaemolyticus strains of the pandemic group in Peru. Material and methods. Clinical and laboratory records were searched in 100 cases of gastroenteritis caused by V parahaemolyticus, either of the pandemic or non pandemic group. Clinical and epidemiological data were collected and statistical analysis was done to evaluate if the severity of illness was associated with the pandemic group. Results. Epidemiological data were collected in 85% of cases, and clinical data were only available in 37% of cases, mainly on those hospitalized. Cases associated with the pandemic strains had a higher probability of liquid stools (96.3% vs. 62.5%, p<0.05), moderate or severe dehydration (100% vs. 60%, p<0.05), and hospital care (98% vs. 42.9%, p<0.0001). Cases aged thirty or older were associated with the pandemic strains (63% vs. 39.5%, p<0.05). Conclusions. Vibrio parahaemolyticus of the pandemic group causes more severe gastrointestinal disease than none pandemic strains, with higher probability of requiring hospital care. Based on this report, it is advisable to include the identification of V. parahaemolyticus in the etiological diagnosis of agents causing severe gastroenteritis in the Peruvian health system.Revisión por pare

Severity of the gastroenteritis caused by Vibrio parahaemolyticus of the pand emic group in Peru

Objective. To determine the epidemiological and clinic characteristics of gastroenteritis caused by Vibrio parahaemolyticus strains of the pandemic group in Peru. Material and methods. Clinical and laboratory records were searched in 100 cases of gastroenteritis caused by V parahaemolyticus, either of the pandemic or non pandemic group. Clinical and epidemiological data were collected and statistical analysis was done to evaluate if the severity of illness was associated with the pandemic group. Results. Epidemiological data were collected in 85% of cases, and clinical data were only available in 37% of cases, mainly on those hospitalized. Cases associated with the pandemic strains had a higher probability of liquid stools (96.3% vs. 62.5%, p<0.05), moderate or severe dehydration (100% vs. 60%, p<0.05), and hospital care (98% vs. 42.9%, p<0.0001). Cases aged thirty or older were associated with the pandemic strains (63% vs. 39.5%, p<0.05). Conclusions. Vibrio parahaemolyticus of the pandemic group causes more severe gastrointestinal disease than none pandemic strains, with higher probability of requiring hospital care. Based on this report, it is advisable to include the identification of V. parahaemolyticus in the etiological diagnosis of agents causing severe gastroenteritis in the Peruvian health system.Revisión por pare

Gravedad de la gastroenteritis causada por vibrio parahaemolyticus del grupo pandémico en el Perú

Objetivos. Determinar las características epidemiológicas y clínicas de la gastroenteritis causada por Vibrio parahaemolyticus del grupo pandémico en el Perú. Materiales y métodos. Se examinó las historias clínicas y registros de laboratorio de cien casos de gastroenteritis en los cuales se aisló V. parahaemolyticus del grupo pandémico y no pandémico. Se recolectó información epidemiológica y clínica y se realizó el análisis estadístico de los datos para evaluar si la gravedad de la enfermedad se asoció con la presencia de las cepas del grupo pandémico. Resultados. Se logró colectar información epidemiológica en 85% de los casos e información clínica sólo en 37% de los casos, principalmente de los hospitalizados. Los casos del grupo pandémico tuvieron una mayor probabilidad de tener deposiciones líquidas (96,3% frente a 62,5%, p<0,05), presentar deshidratación moderada o grave (100% frente a 60%, p<0,05) y requerir atención hospitalaria (98% frente a 42,9%, p<0,0001). Fue más probable aislar una cepa pandémica en personas de 30 o más años de edad (63% frente a 39,5%, p<0,05). Conclusiones. El Vibrio parahaemolyticus del grupo pandémico causa enfermedad gastrointestinal de mayor gravedad que las cepas no pandémicas, con mayor probabilidad de requerir atención hospitalaria. Basados en este reporte, se recomienda incluir la identificación de V. parahaemolyticus en el diagnóstico etiológico de agentes causantes de gastroenteritis grave en el sistema de salud del Perú

Antimicrobial Susceptibility of Brucella melitensis Isolates in Peru▿

Brucellosis is an important public health problem in Peru. We evaluated 48 human Brucella melitensis biotype 1 strains from Peru between 2000 and 2006. MICs of isolates to doxycycline, azithromycin, gentamicin, rifampin, ciprofloxacin, and trimethoprim-sulfamethoxazole were determined by the Etest method. All isolates were sensitive to tested drugs during the periods of testing. Relapses did not appear to be related to drug resistance

The other <i>Campylobacters</i>: Not innocent bystanders in endemic diarrhea and dysentery in children in low-income settings

<div><p>Background</p><p><i>Campylobacter</i> is one of the main causes of gastroenteritis worldwide. Most of the current knowledge about the epidemiology of this food-borne infection concerns two species, <i>C</i>. <i>coli</i> and <i>C</i>. <i>jejuni</i>. Recent studies conducted in developing countries and using novel diagnostic techniques have generated evidence of the increasing burden and importance of other <i>Campylobacter</i> species, i.e. non-<i>C</i>. <i>coli/jejuni</i>. We performed a nested case-control study to compare the prevalence of <i>C</i>. <i>coli/jejuni</i> and other <i>Campylobacter</i> in children with clinical dysentery and severe diarrhea as well as without diarrhea to better understand the clinical importance of infections with <i>Campylobacter</i> species other than <i>C</i>. <i>coli/jejuni</i>.</p><p>Methodology/Principal findings</p><p>Our nested case-control study of 439 stool samples included dysenteric stools, stools collected during severe diarrhea episodes, and asymptomatic stools which were systematically selected to be representative of clinical phenotypes from 9,160 stools collected during a birth cohort study of 201 children followed until two years of age. Other <i>Campylobacter</i> accounted for 76.4% of the 216 <i>Campylobacter</i> detections by qPCR and were more prevalent than <i>C</i>. <i>coli/jejuni</i> across all clinical groups. Other <i>Campylobacter</i> were also more prevalent than <i>C</i>. <i>coli/jejuni</i> across all age groups, with older children bearing a higher burden of other <i>Campylobacter</i>. Biomarkers of intestinal inflammation and injury (methylene blue, fecal occult test, myeloperoxidase or MPO) showed a strong association with dysentery, but mixed results with infection. MPO levels were generally higher among children infected with <i>C</i>. <i>coli/jejuni</i>, but <i>Shigella</i>-infected children suffering from dysentery recorded the highest levels (26,224 ng/mL); the lowest levels (10,625 ng/mL) were among asymptomatic children infected with other <i>Campylobacter</i>. Adjusting for age, sex, and <i>Shigella</i> infection, dysentery was significantly associated with <i>C</i>. <i>coli/jejuni</i> but not with other <i>Campylobacter</i>, whereas severe diarrhea was significantly associated with both <i>C</i>. <i>coli/jejuni</i> and other <i>Campylobacter</i>. Compared to asymptomatic children, children suffering from dysentery had a 14.6 odds of <i>C</i>. <i>coli/jejuni</i> infection (p-value < 0.001, 95% CI 5.5–38.7) but were equally likely to have other <i>Campylobacter</i> infections–odds ratio of 1.3 (0.434, 0.7–2.4). Children suffering from severe diarrhea were more likely than asymptomatic children to test positive for both <i>C</i>. <i>coli/jejuni</i> and other <i>Campylobacter</i>–OR of 2.8 (0.034, 1.1–7.1) and 1.9 (0.018, 1.1–3.1), respectively. Compared to the <i>Campylobacter</i>-free group, the odds of all diarrhea given <i>C</i>. <i>coli/jejuni</i> infection and other <i>Campylobacter</i> infection were 8.8 (<0.001, 3.0–25.7) and 2.4 (0.002, 1.4–4.2), respectively. Eliminating other <i>Campylobacter</i> in this population would eliminate 24.9% of the diarrhea cases, which is almost twice the population attributable fraction of 15.1% due to <i>C</i>. <i>coli/jejuni</i>.</p><p>Conclusions/Significance</p><p>Eighty-seven percent of the dysentery and 59.5% of the severe diarrhea samples were positive for <i>Campylobacter</i>, <i>Shigella</i>, or both, emphasizing the importance of targeting these pathogens to limit the impact of dysentery and severe diarrhea in children. Notably, the higher prevalence of other <i>Campylobacter</i> compared to <i>C</i>. <i>coli/jejuni</i>, their increasing burden during early childhood, and their association with severe diarrhea highlight the importance of these non-<i>C</i>. <i>coli/jejuni Campylobacter</i> species and suggest a need to clarify their importance in the etiology of clinical disease across different epidemiological contexts.</p></div

Prevalence of <i>Campylobacter</i> and <i>Shigella</i> among children suffering from dysentery and severe diarrhea in peri-urban communities in Loreto, Peru.

<p>Prevalence of <i>Campylobacter</i> and <i>Shigella</i> among children suffering from dysentery and severe diarrhea in peri-urban communities in Loreto, Peru.</p

List of primers and probes used for the detection of <i>Campylobacter</i> (genus specific), <i>Campylobacte</i>r <i>coli/jejuni</i>, and <i>Shigella</i>.

<p>List of primers and probes used for the detection of <i>Campylobacter</i> (genus specific), <i>Campylobacte</i>r <i>coli/jejuni</i>, and <i>Shigella</i>.</p

<i>C</i>. <i>coli/jejuni</i>, other <i>Campylobacter</i>, and <i>Shigella</i> prevalence by clinical outcome (asymptomatic infection, dysentery, severe diarrhea) using the qPCR assay.

<p><i>C</i>. <i>coli/jejuni</i>, other <i>Campylobacter</i>, and <i>Shigella</i> prevalence by clinical outcome (asymptomatic infection, dysentery, severe diarrhea) using the qPCR assay.</p